The Lubinus SP II stem is a well-documented prosthesis ([@CIT0001], [@CIT0011], [@CIT0004], [@CIT0020]). The anatomical-shaped SP stem was introduced in 1982 as a monoblock prosthesis, and since 1984 it has been available as the modular SP II system. The anatomical-shaped stem provides a uniform cement mantle surrounding the prosthesis, which reduces the risk of contact between the prosthesis and cortical bone. It has been hypothesized that this more uniform cement mantle improves the survival of the prosthesis ([@CIT0011]). Worldwide, the most commonly used stem lengths are 150 and 170 mm. In 1995, the 130-mm stem was introduced and since its introduction this has been the most frequently used stem in our hospital. This shorter stem has several theoretical advantages, such as preservation of bone stock and possibly a better filling of the proximal femur, subsequently leading to better options for revision. Theoretically, however, the shorter stem has less rotational stability.

There is no literature specifically about the SP II 130-mm stem. Reports on 150-mm and 170-mm SP II stems show survival rates ranging from 90% to 98%, with a minimum of 10 years of follow-up ([@CIT0001], [@CIT0011], [@CIT0004], [@CIT0012], [@CIT0006], [@CIT0020]). The Swedish registry data are almost uniformly (\> 98%) based on the 150-mm stem ([@CIT0017]). We hypothesized that the long-term survival of the Lubinus SP II 130-mm stem in primary total hip arthroplasty would be no different from the reported survival of the 150-mm and 170-mm SP II femoral stems. This hypothesis was tested in a retrospective cohort study using revision for any reason as the primary endpoint.

Patients and methods {#ss1}
====================

Source of data {#ss2}
--------------

Data were extracted from the medical registration system, calling the patients and consulting the patients' (former) general practitioners (GPs). If patients had died, their relatives or GPs were asked if any revision of the total hip arthroplasty had occurred.

Study population {#ss3}
----------------

Between July 1996 and December 2001, a total of 1,248 total hip arthroplasties were performed at our hospital. In 932 primary hip arthroplasties (in 829 patients), the Lubinus SP II was used (Waldemar Link, Hamburg, Germany). We included all patients with a primary total arthroplasty of the hip with the Lubinus SP II 130 mm. Selection criteria for a cemented SP II prosthesis were mainly based on older age (\> 60 years) and radiographic bone quality. However, the anatomical length of the femur was not considered. In this period, younger patients with sufficient bone quality mainly received uncemented femoral prostheses. Their results have been published ([@CIT0007]). Also in this period, we used the 170-mm SP II in selected cases (\< 20 patients) with insufficient proximal bone stock due to secondary osteoarthritis (e.g. posttraumatic). Until 2000, the 130-mm Lubinus SP II stem was combined with a Co-Cr-Mo 28-mm head and a Lubinus IP cup (Waldemar Link). In 2000, the IP cup was replaced with the Flanged Anti Luxation (FAL) cup (Waldemar Link) with 28-mm Biolox-forte ceramic head (CeramTec, Plochingen, Germany). All components were cemented using Simplex bone cement (Stryker).

The Lubinus SP II is an anatomical, S-shaped modular stem (of Co-Cr-Mo) with an anatomical anteversion and a 12- to 14-mm taper ([Figure 1](#F1){ref-type="fig"}). The stem is available in 7 sizes (left and right) and 3 different caput collum diaphysis (CCD) angles (117°, 126°, and 135°). The applied IP and FAL acetabular components are cemented polyethylene cups in eight different sizes ranging from 44 mm to 58 mm with an inner diameter of 28 mm.

![The anatomical S-shaped Lubinus SP II stem.](ORT-85-276-g001){#F1}

829 patients (932 hips) were included in the study. 103 patients were operated bilaterally ([Table 1](#T1){ref-type="table"}). The mean follow-up period was 10 (5--15) years. During the follow-up period, 400 patients died and 21 (2%) were lost to follow-up. Furthermore, 29 patients had a follow-up of less than 5 years and were excluded from the risk factor analysis (but were included in the Kaplan-Meier curve).

###### 

Demographics

  --------------------------- -----------
  Age                         
   Mean, years (SD)           72 (8.0)
  Sex                         
   Men                        223 (24%)
   Women                      709 (76%)
  Side of surgery             
   Right                      467 (50%)
   Left                       465 (50%)
  Preoperative diagnosis      
   Primary osteoarthritis     863 (93%)
   Secondary osteoarthritis   52 (5.6%)
   Inflammatory diseases      35 (3.8%)
   Avascular necrosis         6 (0.6%)
   Childhood diseases         1 (0.1%)
   Other                      10 (1.1%)
   Fracture                   17 (1.8%)
  Stem size                   
   01                         15 (1.6%)
   1                          268 (29%)
   2                          277 (30%)
   3                          247 (27%)
   4                          123 (13%)
   5                          1 (0.1%)
  --------------------------- -----------

In all but 2 hips (one 117° and one 135°), the 126° CCD angle was used.

All patients had surgery in the lateral decubitus position with a posterolateral or anterolateral approach, depending on the preference of the surgeon. In the study period, line-to-line cementing to the last broach was used and the prosthesis was rarely undersized. 5 different surgeons performed the surgery. Perioperatively, systemic antibiotic prophylaxis was given (cefazoline). Patients received low-molecular-weight heparin (LMWH) until adequate INR, and a vitamin K antagonist, which was continued until 3 months after surgery. Patients were allowed and encouraged to start full weight bearing on the first postoperative day.

Statistics {#ss4}
----------

The follow-up period started on the day of implantation of the THA. It ended on the day of revision, death, or last available follow-up measurement until April 30, 2012. Kaplan-Meier survival analyses were performed for the total hip arthroplasty, the cup, and the stem. We also performed analysis of the first implanted hip as for all hips. Some studies have found that bilaterally implanted THAs show better survival than unilaterally implanted hips ([@CIT0021]). However, other studies have found that this possible bias is negligible (Robertson and Ranstam 2003, [@CIT0010]).

Standard-case, worst-case, and best-case scenarios were analyzed.

Cox regression analysis was then conducted to identify independent risk factors that would best explain revision of the stem in our population over 5 or more years of follow-up. In Cox regression, only the first implanted hip (in patients with a bilateral THA) was used, to avoid dependency of data from bilateral arthroplasties. The potential risk factors selected for this analysis were age, sex, and diagnosis (based on dummy variables using arthrosis as reference). Only significant factors in the bilateral analysis were subsequently fitted into a multivariable analysis based on a stepwise-backward selection procedure. However, as the bilateral analysis did not generate any significant factors and the analysis did not comply with the assumptions, this multivariable stage of the analysis was not reached and---as a consequence---no independent risk factors for stem revision could be identified. Assumptions were assessed by evaluating log-log plots. 95% confidence intervals were calculated.

A 2-sided p-value of \< 0.05 was considered to be statistically significant.

All statistical analyses were performed using SPSS software version 20.0.

Results {#ss5}
=======

Survival {#ss6}
--------

The best-case scenario was a 10-year survival of 98.7% (CI: 99.7--97.7) for the stem. In the worst-case scenario, we found a 10-year survival of 96.1% (CI: 94.9--97.3) for the stem ([Figure 2](#F2){ref-type="fig"} and [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

![Survival curves for the THA and stem: all-cause survival of the THA (blue line), all-cause survival of the stem (green line), and aseptic survival of the stem (orange line). Dotted lines show confidence intervals for the respective survival curves.](ORT-85-276-g002){#F2}

###### 

Survival rates at 10 years for THA, stem, and cup [**^a^**](#T2-F1){ref-type="fn"} (with all hips included)

                            THA (95% CI)        Stem (95% CI)       Cup (95% CI)
  ------------------------- ------------------- ------------------- -------------------
  Revision for any reason   98.3 (99.3--97.3)   98.7 (99.7--97.7)   98.7 (99.7--97.7)
  Aseptic loosening         99.2 (99.9--98.4)   99.4 (99.9--98.4)   99.7 (100--99.3)

**^a^** After 10 years, 406 patients were at risk.

###### 

Survival rates at 10 years for THA, stem, and cup [**^a^**](#T3-F1){ref-type="fn"} a (with only the first implanted hip included)

                            THA (95% CI)        Stem (95% CI)       Cup (95% CI)
  ------------------------- ------------------- ------------------- -------------------
  Revision for any reason   98.6 (99.6--97.6)   98.9 (99.9--97.9)   99.0 (99.8--98.2)
  Aseptic loosening         99.4 (100--98.6)    99.3 (99.9--98.7)   99.8 (100--99.4)

**^a^** After 10 years, 357 patients were at risk.

In the multivariable Cox regression analysis, we failed to identify a single risk factor (from sex, side, femoral stem size, and preoperative diagnosis) for stem revision.

Discussion {#ss7}
==========

We found excellent 10-year survival rates (∼99%) for the relatively short 130-mm Lubinus SP II stem, for aseptic loosening and for all-cause revision. The relatively unknown 130-mm SP II stem has several potential advantages over the larger 150-mm and 170-mm stems. First, the shorter stem preserves bone distal to the prosthesis. Secondly, the proximal filling might be better with the use of this shorter stem, leading to a more even distribution of cement---especially in Dorr type A (champagne-fluted) femora. Thirdly, in our experience this stem is more easily removed from its cement mantle than its longer peers, giving the opportunity of cement-in-cement revision. Theoretically, the shorter stem design could result in less rotational stability compared to the 150-mm and 170-mm siblings. This disadvantage does not appear to influence survival, possibly because of better proximal filling, which has promoted rotational stability in experimental studies ([@CIT0009]).

We believe that our results are valid because we had a negligible loss-to-follow-up rate (2%). Even in the worst-case scenario, the survival rate was 96.1% at 10-year follow-up.

The study had some potential weaknesses. First, we did not evaluate the clinical and radiographic condition of the patients. The clinical results could therefore have been worse than the survival data suggest, a weakness that also occurs in registry-based studies. Our patients were relatively old (mean age: 72.3 years) and our results may not apply to the younger age group. In several studies, young age has been considered to be a risk factor for revision ([@CIT0014]).

There is an ongoing discussion about whether to use cemented or uncemented designs ([@CIT0008], [@CIT0005]). A recently published randomized controlled trial performed by [@CIT0005] showed clearly favorable results regarding the cementless stem in the younger population. [@CIT0008] reviewed information from the Swedish Hip Arthroplasty Register (SHAR) to compare cemented and cementless femoral stems. They found superior survival in the cemented stems. Stratification into age groups showed inferior survival rates for the cementless stem, except for the age group \> 75 years ([@CIT0008]). Our study supports the use of the cemented shorter 130-mm stem in older patients especially.

Compared to commonly used straight stem designs, the anatomical-shaped Lubinus SP II has better centralization of the stem, which leads to more even thickness of the cement mantle ([@CIT0003]). One study showed that the Lubinus SP II had the lowest number of cement cracks compared to 3 other cemented stem designs ([@CIT0016]). Other studies have shown less than 1% cracks in the cement mantle (compared to 6% and 8% for the Charnley and Exeter stems, respectively) ([@CIT0013], [@CIT0019]). The relevance of these mechanical advantages is debatable, since all stem designs in these studies have excellent survival.

We found no effect of stem size, even though the survival of the smallest 01 SP II stem is reportedly inferior to that of the larger stems ([@CIT0018]). Only 1% of patients in our population were fitted with the smallest stem size. This is most likely due to better proximal filling and line-to-line cementing, allowing a larger stem size to be inserted when using the shorter 130-mm SP II.

We did not adjust the length of the SP II to the length of the femur, and instead used the 130-mm SP II stem in all patients with normal proximal bone stock. We could not find any literature regarding tailoring of the stem length to the anatomical length of the femur. The equally favourable results obtained in men and women also suggest that this is not an important factor with the cemented SP II stem. Furthermore, there is some evidence that shorter (uncemented) stems provide more anatomical strain in the proximal femur ([@CIT0002]).

In summary, we found excellent survival results (98.6% all-cause and 99% for aseptic loosening) of the relatively short cemented Lubinus SP II 130-mm stem. Because of the excellent survival rate, preservation of bone stock, and the advantages in revision hip arthroplasty, we recommend using the 130-mm SP II stem over use of its longer siblings.
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